{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T07:46:22Z","timestamp":1768722382006,"version":"3.49.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"suppl_5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11,15]]},"DOI":"10.1093\/cid\/civ626","type":"journal-article","created":{"date-parts":[[2015,11,9]],"date-time":"2015-11-09T19:33:10Z","timestamp":1447097590000},"page":"S507-S513","source":"Crossref","is-referenced-by-count":5,"title":["A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians"],"prefix":"10.1093","volume":"61","author":[{"given":"Milagritos D.","family":"Tapia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samba O.","family":"Sow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadima Cheick","family":"Haidara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatoumata","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moussa","family":"Doumbia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godwin C.","family":"Enwere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gandhali","family":"Paranjape","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Herv\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enricke","family":"Bouma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varsha","family":"Parulekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Martellet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Chaumont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D.","family":"Plikaytis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Pierre","family":"Preziosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,11,9]]},"reference":[{"key":"key\n\t\t\t\t20171014002628_CIV626C1","first-page":"61","article-title":"The epidemiology of acute bacterial meningitis in tropical Africa","volume-title":"Bacterial meningitis","year":"1987"},{"key":"key\n\t\t\t\t20171014002628_CIV626C2","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0140-6736(03)13494-0","article-title":"Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries","volume":"361","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014002628_CIV626C3","article-title":"Immunization standards: meningococcal A conjugate 10 dose presentation","author":"World Health Organization"},{"key":"key\n\t\t\t\t20171014002628_CIV626C4","article-title":"Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults","volume":"25 suppl 1:A101\u20137","year":"2007","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014002628_CIV626C5","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal A conjugate vaccine in African","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014002628_CIV626C6","first-page":"6456","article-title":"Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2\u201310 years: a phase II\/III double-blind randomized controlled trial","volume":"30","year":"2010","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014002628_CIV626C7","first-page":"29","article-title":"Global Advisory Committee on Vaccine Safety, 3\u20134 December 2009","volume":"85","year":"2010","journal-title":"Wkly Epidemiol Rec"},{"key":"key\n\t\t\t\t20171014002628_CIV626C8","first-page":"285","article-title":"Global Advisory Committee on Vaccine Safety, 16\u201317 June 2010","volume":"85","year":"2010","journal-title":"Wkly Epidemiol Rec"},{"key":"key\n\t\t\t\t20171014002628_CIV626C9","first-page":"1","article-title":"Guideline on clinical evaluation of new vaccines","author":"European Agency for the Evaluation of Medicinal Products (EMEA)","year":"2006"},{"key":"key\n\t\t\t\t20171014002628_CIV626C10","first-page":"1","article-title":"ICH harmonized tripartite guideline","author":"International Committee on Harmonisation","year":"2000"},{"key":"key\n\t\t\t\t20171014002628_CIV626C11","article-title":"Guidelines on clinical evaluation of vaccines: regulatory expectations","author":"World Health Organization","year":"2004"},{"key":"key\n\t\t\t\t20171014002628_CIV626C12","article-title":"Recommendations to assure the quality, safety and efficacy of group A meningococcal conjugate vaccines","author":"World Health Organization","year":"2006"},{"key":"key\n\t\t\t\t20171014002628_CIV626C13","article-title":"Management of safety information from clinical trials","author":"Council for International Organizations of Medical Sciences"},{"key":"key\n\t\t\t\t20171014002628_CIV626C14","first-page":"1","article-title":"ICH harmonized tripartite guideline","author":"International Committee on Harmonisation","year":"2004"},{"key":"key\n\t\t\t\t20171014002628_CIV626C15","first-page":"143","volume-title":"Sample size tables for clinical studies","year":"1997","edition":"2nd ed."},{"key":"key\n\t\t\t\t20171014002628_CIV626C16","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","year":"1990","journal-title":"Stat Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/61\/suppl_5\/S507\/20914572\/civ626.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T00:26:33Z","timestamp":1507940793000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/61\/suppl_5\/S507\/418712\/A-Phase-3-DoubleBlind-Randomized-Active-Controlled"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,9]]},"references-count":16,"journal-issue":{"issue":"suppl_5","published-online":{"date-parts":[[2015,11,9]]},"published-print":{"date-parts":[[2015,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/civ626","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,11,15]]},"published":{"date-parts":[[2015,11,9]]}}}